CME/CE

This series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE and offer strategies for timely diagnosis. The discussion covers practical tools for detection, the role of nutrition and pharmacologic therapy, and evidence-based approaches to prevent progression and hospitalization. Emerging therapies and ongoing clinical trials are also discussed to highlight future directions in HE treatment.

This series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE and offer strategies for timely diagnosis. The discussion covers practical tools for detection, the role of nutrition and pharmacologic therapy, and evidence-based approaches to prevent progression and hospitalization. Emerging therapies and ongoing clinical trials are also discussed to highlight future directions in HE treatment.

This series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE and offer strategies for timely diagnosis. The discussion covers practical tools for detection, the role of nutrition and pharmacologic therapy, and evidence-based approaches to prevent progression and hospitalization. Emerging therapies and ongoing clinical trials are also discussed to highlight future directions in HE treatment.

This series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE and offer strategies for timely diagnosis. The discussion covers practical tools for detection, the role of nutrition and pharmacologic therapy, and evidence-based approaches to prevent progression and hospitalization. Emerging therapies and ongoing clinical trials are also discussed to highlight future directions in HE treatment.

This CME activity focuses on enhancing clinician recognition and management of autosomal dominant hypocalcemia type 1 (ADH1). Learners will explore the pathophysiology and clinical manifestations of ADH1, understand barriers to timely diagnosis, gain practical strategies for implementing and interpreting genetic testing, and evaluate emerging therapies—such as calcilytics—that target CaSR mutations. By improving diagnostic accuracy, enabling timely and evidence-based interventions, and improving knowledge of emerging treatments, this activity aims to advance clinical outcomes for patients with ADH1.

This three-part educational activity reviews the burden of respiratory syncytial virus (RSV) and evidence-based strategies to prevent disease in infants and young children. Chapter 1 examines the epidemiology of RSV and outlines current prophylactic options, including maternal vaccination and the monoclonal antibodies nirsevimab (approved 2023) and clesrovimab (approved 2025). Chapter 2 summarizes American Academy of Pediatrics (AAP) recommendations with guidance on timing, maternal vaccination status, coadministration, and the importance of hospital-based immunization for newborns. Chapter 3 focuses on effective parent–clinician communication, emphasizing shared decision-making, addressing concerns and misinformation, and supporting timely immunization to reduce RSV-related morbidity and mortality.

Expert faculty Drs. Luca Busetto and Kirsi H. Pietiläinen discuss the importance of early intervention in obesity management to prevent progression and obesity related complications. They examine the evolving therapeutic landscape, including GLP-1 and GIP-based medications like semaglutide and tirzepatide. The conversation highlights real-world evidence and addresses the shift from weight-centric to holistic clinical approaches, as seen in updated European and Canadian guidelines. Monitoring strategies—including satiety, nutritional status, physical activity, and side effects—are explored as key elements in long-term obesity care. The dialogue underscores the chronic nature of obesity and the importance of patient-centered care.

In this Chairperson’s Perspective, Dr. Jose Rubio and Dr. Jonathan Meyer explore the evolving landscape of schizophrenia treatment through muscarinic receptor modulation. They compare the mechanisms of action, efficacy, and side effect profiles of muscarinic antipsychotics, such as xanomeline-trospium, with traditional dopamine D2 antagonists. The discussion addresses key clinical considerations for transitioning between dopaminergic and muscarinic therapies, including cholinergic burden and cross-titration timing. This expert dialogue provides relevant guidance for clinicians aiming to incorporate muscarinic therapies into personalized treatment plans for schizophrenia.

On-demand webcast with expert faculty presentation on addressing the unmet needs and optimizing treatment for hereditary angioedema (HAE), including long-term prophylaxis therapy, for patients with HAE.

This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.